JAK1 somatic mutation in a myeloproliferative neoplasm.

about

JAK1 somatic mutation in a myeloproliferative neoplasm.

Item

http://www.wikidata.org/entity/Q42341710

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

JAK1 somatic mutation in a myeloproliferative neoplasm.

@en

JAK1 somatic mutation in a myeloproliferative neoplasm.

@nl

type

Item

label

JAK1 somatic mutation in a myeloproliferative neoplasm.

@en

JAK1 somatic mutation in a myeloproliferative neoplasm.

@nl

prefLabel

JAK1 somatic mutation in a myeloproliferative neoplasm.

@en

JAK1 somatic mutation in a myeloproliferative neoplasm.

@nl

P1476

JAK1 somatic mutation in a myeloproliferative neoplasm.

@en

P2093

Debbie Taylor

http://www.w3.org/2001/XMLSchema#string

Graham Magor

http://www.w3.org/2001/XMLSchema#string

Hock-Lai Choong

http://www.w3.org/2001/XMLSchema#string

Ian M Irving

http://www.w3.org/2001/XMLSchema#string

Paula Ambrosoli

http://www.w3.org/2001/XMLSchema#string

Suzanne O Arulogun

http://www.w3.org/2001/XMLSchema#string

Tee-Beng Keng

http://www.w3.org/2001/XMLSchema#string

P2860

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhi

P304

e324-e327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2017.170266

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Andrew C Perkins

P577

2017-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28550193

http://www.w3.org/2001/XMLSchema#string

P932

5541888

http://www.w3.org/2001/XMLSchema#string